Safety and tolerability of inebilizumab (MEDI-551), an anti-CD19 monoclonal antibody, in patients with relapsing forms of multiple sclerosis: results from a phase 1 …

MA Agius, G Klodowska-Duda… - Multiple Sclerosis …, 2019 - journals.sagepub.com
Background: B cells may be involved in the pathophysiology of multiple sclerosis (MS).
Inebilizumab (formerly MEDI-551) binds to and depletes CD19+ B cells. Objectives: To …
被引用次数：119 相关文章

Safety and tolerability of inebilizumab (MEDI-551), an anti-CD19 monoclonal antibody, in patients with relapsing forms of multiple sclerosis: Results from a phase 1 …

MA Agius, G Klodowska-Duda… - Multiple Sclerosis …, 2017 - europepmc.org
BACKGROUND: B cells may be involved in the pathophysiology of multiple sclerosis (MS).
Inebilizumab (formerly MEDI-551) binds to and depletes CD19+ B cells. OBJECTIVES: To …
[PDF] academia.edu

[PDF][PDF] Mark A Agius, Gabriela Klodowska-Duda, Maciej Maciejowski, Andrzej Potemkowski, Jing Li, Kaushik Patra, Jacob Wesley, Soraya Madani, Gerard Barron …

MA Agius - Multiple Sclerosis Journal, 2019 - academia.edu
Background: B cells may be involved in the pathophysiology of multiple sclerosis (MS).
Inebilizumab (formerly MEDI-551) binds to and depletes CD19+ B cells. Objectives: To …

Safety and tolerability of inebilizumab (MEDI-551), an anti-CD19 monoclonal antibody, in patients with relapsing forms of multiple sclerosis: Results from a phase 1 …

MA Agius, G Klodowska-Duda, M Maciejowski… - 2017 - hero.epa.gov
BACKGROUND: B cells may be involved in the pathophysiology of multiple sclerosis (MS).
Inebilizumab (formerly MEDI-551) binds to and depletes CD19+ B cells. OBJECTIVES: To …
[HTML] nih.gov

[HTML][HTML] Safety and tolerability of inebilizumab (MEDI-551), an anti-CD19 monoclonal antibody, in patients with relapsing forms of multiple sclerosis: Results from a …

MA Agius, G Klodowska-Duda… - Multiple Sclerosis …, 2019 - ncbi.nlm.nih.gov
Background: B cells may be involved in the pathophysiology of multiple sclerosis (MS).
Inebilizumab (formerly MEDI-551) binds to and depletes CD19+ B cells. Objectives: To …

Safety and tolerability of inebilizumab (MEDI-551), an anti-CD19 monoclonal antibody, in patients with relapsing forms of multiple sclerosis: Results from a phase 1 …

MA Agius, G Barron… - Multiple Sclerosis …, 2019 - search.ebscohost.com
Background: B cells may be involved in the pathophysiology of multiple sclerosis (MS).
Inebilizumab (formerly MEDI-551) binds to and depletes CD19+ B cells. Objectives: To …

Safety and tolerability of inebilizumab (MEDI-551), an anti-CD19 monoclonal antibody, in patients with relapsing forms of multiple sclerosis: Results from a phase 1 …

MA Agius, G Klodowska-Duda, M Maciejowski… - Multiple Sclerosis …, 2017 - cir.nii.ac.jp
抄録< jats: sec>< jats: title> Background:</jats: title>< jats: p> B cells may be involved in the
pathophysiology of multiple sclerosis (MS). Inebilizumab (formerly MEDI-551) binds to and …

Safety and tolerability of inebilizumab (MEDI-551), an anti-CD19 monoclonal antibody, in patients with relapsing forms of multiple sclerosis: Results from a phase 1 …

MA Agius, G Klodowska-Duda… - Multiple sclerosis …, 2019 - pubmed.ncbi.nlm.nih.gov
Background B cells may be involved in the pathophysiology of multiple sclerosis (MS).
Inebilizumab (formerly MEDI-551) binds to and depletes CD19+ B cells. Objectives To …

Safety and tolerability of inebilizumab (MEDI-551), an anti-CD19 monoclonal antibody, in patients with relapsing forms of multiple sclerosis: Results from a phase 1 …

MA Agius, G Klodowska-Duda… - Multiple Sclerosis …, 2017 - europepmc.org
BACKGROUND: B cells may be involved in the pathophysiology of multiple sclerosis (MS).
Inebilizumab (formerly MEDI-551) binds to and depletes CD19+ B cells. OBJECTIVES: To …
[PDF] academia.edu

[PDF][PDF] Mark A Agius, Gabriela Klodowska-Duda, Maciej Maciejowski, Andrzej Potemkowski, Jing Li, Kaushik Patra, Jacob Wesley, Soraya Madani, Gerard Barron …

MA Agius - Multiple Sclerosis Journal, 2019 - academia.edu
Background: B cells may be involved in the pathophysiology of multiple sclerosis (MS).
Inebilizumab (formerly MEDI-551) binds to and depletes CD19+ B cells. Objectives: To …